Blueprint Medicines Co. to Post Q1 2025 Earnings of ($1.71) Per Share, Zacks Research Forecasts (NASDAQ:BPMC)

Posted by on Jun 23rd, 2023

Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) – Research analysts at Zacks Research lowered their Q1 2025 earnings per share (EPS) estimates for Blueprint Medicines in a research note issued to investors on Monday, June 19th. Zacks Research analyst A. Chakraborty now expects that the biotechnology company will earn ($1.71) per share for the quarter, down from their prior forecast of ($1.63). The consensus estimate for Blueprint Medicines’ current full-year earnings is ($9.55) per share. Zacks Research also issued estimates for Blueprint Medicines’ FY2025 earnings at ($6.83) EPS.

Blueprint Medicines (NASDAQ:BPMC – Get Rating) last released its quarterly earnings data on Thursday, May 4th. The biotechnology company reported ($2.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.66) by $0.51. The firm had revenue of $63.29 million during the quarter, compared to analyst estimates of $41.85 million. Blueprint Medicines had a negative return on equity of 100.31% and a negative net margin of 284.02%. The business’s quarterly revenue was up .9% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.79) earnings per share.

Other equities analysts have also issued reports about the company. Barclays increased their price target on Blueprint Medicines from $44.00 to $46.00 in a research note on Tuesday, May 23rd. HC Wainwright increased their price target on Blueprint Medicines from $75.00 to $85.00 in a research note on Tuesday, May 23rd. StockNews.com initiated coverage on Blueprint Medicines in a research note on Thursday, May 18th. They set a “hold” rating for the company. SVB Securities lowered Blueprint Medicines from a “market perform” rating to an “underperform” rating and dropped their price target for the company from $48.00 to $43.00 in a research note on Monday, June 5th. Finally, SVB Leerink lowered Blueprint Medicines from a “market perform” rating to an “underperform” rating in a research note on Monday, June 5th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $75.67.

Blueprint Medicines Stock Performance

NASDAQ BPMC opened at $64.08 on Thursday. The business has a 50-day moving average price of $55.10 and a 200-day moving average price of $48.50. Blueprint Medicines has a twelve month low of $37.82 and a twelve month high of $79.40. The firm has a market cap of $3.87 billion, a price-to-earnings ratio of -6.60 and a beta of 0.71. The company has a quick ratio of 5.11, a current ratio of 5.21 and a debt-to-equity ratio of 0.29.

Institutional Trading of Blueprint Medicines

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Bessemer Group Inc. bought a new stake in Blueprint Medicines during the 1st quarter valued at $36,000. Van ECK Associates Corp boosted its position in shares of Blueprint Medicines by 51.2% in the 4th quarter. Van ECK Associates Corp now owns 986 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 334 shares in the last quarter. Lazard Asset Management LLC acquired a new stake in shares of Blueprint Medicines in the 4th quarter worth $57,000. Dark Forest Capital Management LP acquired a new stake in shares of Blueprint Medicines in the 1st quarter worth $63,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Blueprint Medicines in the 1st quarter worth $95,000.

Insiders Place Their Bets

In other Blueprint Medicines news, insider Percy H. Carter sold 2,307 shares of the stock in a transaction on Monday, June 5th. The stock was sold at an average price of $52.06, for a total transaction of $120,102.42. Following the sale, the insider now owns 38,117 shares of the company’s stock, valued at approximately $1,984,371.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 3.88% of the stock is currently owned by company insiders.

Blueprint Medicines Company Profile

(Get Rating)

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and Fisogatinib.

Featured Articles

Earnings History and Estimates for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.